- MSDC 0160
-
- $70.00 / 5mg
-
2025-04-28
- CAS:146062-49-9
- Min. Order:
- Purity: 99.45%
- Supply Ability: 10g
|
| | CAY10415 Basic information |
| Product Name: | CAY10415 | | Synonyms: | CAY10415;MSDC-0160;CAY10415;CAY-10415;CAY 10415;MSDC 0160;MSDC0160;CS-1615;MITOGLITAZONE;CAY10415;MSDC 0160;2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-;CAY10415 (Mitoglitazone);Mitoglitazone | | CAS: | 146062-49-9 | | MF: | C19H18N2O4S | | MW: | 370.42 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 146062-49-9.mol |  |
| | CAY10415 Chemical Properties |
| Boiling point | 623.8±55.0 °C(Predicted) | | density | 1.315±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | ≥37 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | | form | A crystalline solid | | pka | 6.32±0.50(Predicted) | | color | white to beige |
| | CAY10415 Usage And Synthesis |
| Uses | CAY10415 is used to study blood glucose levels and rates of insulin-stimulated lipogenesis. | | Definition | ChEBI: 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]thiazolidine-2,4-dione is an aromatic ether. | | Biological Activity | msdc-0160 is a prototype mtot-modulating insulin sensitizer [1].msdc-0160 is a thiazolidinedione insulin sensitizer without the peroxisome proliferator–activated receptor-γ (ppar-γ)-dependent side effects. co-incubation of islets with msdc-0160 and igf-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. msdc-0160 at 50μm alone also prevents the loss of insulin content significantly. besides that, treatment of msdc-0160 increases the phosphorylation of ampk and reduces mtor phosphorylation. moreover, msdc-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. in addition, msdc-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells [1]. | | in vivo | MSDC 0160 (Mitoglitazone; 30 mg/kg; oral gavage; daily; for 7 days) improves locomotor behavior, increases survival of nigral dopaminergic neurons, boosts striatal dopamine levels, and reduces neuroinflammation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice[2].
| Animal Model: | Ten- to 12-week-old male C57BL/6J mice weighing 24 to 28 g[2] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage; daily; for 7 days | | Result: | Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.
|
| | references | [1] rohatgi n, aly h, marshall c a, et al. novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets. plos one, 2013, 8(5): e62012. |
| | CAY10415 Preparation Products And Raw materials |
|